MedTrace Logo

Treatment of Tuberculosis Multidrug Resistance Treatment of Tuberculosis Multidrug Resistance

NCT03057756 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 23

Last updated 2026-03-17

No results posted yet for this study

Summary

The principal objective is to evaluate a cure rate and number of adverse events of with confirmed multidrug-resistant tuberculosis patient treated with a 9months regimen.

Conditions

  • Multi-drug Resistant Tuberculosis

Interventions

COMBINATION_PRODUCT

Km+ Mfx+ Pto + H + Cfz +E+Z

Second generation of anti tuberculosis Kanamycine, Moxifloxacine,Prothionamide, isoniazide,Clofazimine, Ethambutol,Pyrazinamide

Sponsors & Collaborators

  • Institute of Tropical Medicine, University of Tuebingen

    collaborator OTHER

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    collaborator OTHER

  • Centre de Recherche Médicale de Lambaréné

    lead OTHER

Principal Investigators

  • Ayola A Adegnika, MD, PhD · Centre de Recherches Médicales de Lambaréné

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-09-11
Primary Completion
2023-04-04
Completion
2023-05-01

Countries

  • Gabon

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03057756 on ClinicalTrials.gov